Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois Sells 2,824 Shares

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) CEO Cedric Francois sold 2,824 shares of the company’s stock in a transaction on Wednesday, January 29th. The stock was sold at an average price of $29.52, for a total value of $83,364.48. Following the sale, the chief executive officer now directly owns 415,695 shares in the company, valued at $12,271,316.40. This represents a 0.67 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Cedric Francois also recently made the following trade(s):

• On Wednesday, January 22nd, Cedric Francois sold 13,551 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $30.43, for a total transaction of $412,356.93.
• On Friday, January 17th, Cedric Francois sold 6,007 shares of Apellis Pharmaceuticals stock. The stock was sold at an average price of $29.96, for a total value of $179,969.72.
• On Monday, January 13th, Cedric Francois sold 6,247 shares of Apellis Pharmaceuticals stock. The shares were sold at an average price of $28.70, for a total transaction of $179,288.90.

Apellis Pharmaceuticals Stock Up 3.1 %

NASDAQ:APLS opened at $30.39 on Friday. The business’s fifty day moving average price is $32.24 and its 200 day moving average price is $32.95. Apellis Pharmaceuticals, Inc. has a 1-year low of $24.34 and a 1-year high of $71.90. The firm has a market capitalization of $3.78 billion, a price-to-earnings ratio of -14.97 and a beta of 0.94. The company has a current ratio of 4.36, a quick ratio of 3.73 and a debt-to-equity ratio of 1.91.

Apellis Pharmaceuticals (NASDAQ:APLS) last posted its earnings results on Tuesday, November 5th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.32) by ($0.14). The company had revenue of $196.83 million during the quarter, compared to analyst estimates of $200.00 million. Apellis Pharmaceuticals had a negative return on equity of 103.11% and a negative net margin of 34.97%. The firm’s revenue for the quarter was up 78.3% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.17) earnings per share. On average, sell-side analysts forecast that Apellis Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several research firms have commented on APLS. Needham & Company LLC cut their price target on Apellis Pharmaceuticals from $85.00 to $60.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. Mizuho decreased their price target on shares of Apellis Pharmaceuticals from $39.00 to $38.00 and set a “neutral” rating for the company in a research note on Thursday, October 24th. Oppenheimer dropped their price objective on shares of Apellis Pharmaceuticals from $65.00 to $40.00 and set an “outperform” rating on the stock in a research note on Wednesday, November 6th. William Blair assumed coverage on shares of Apellis Pharmaceuticals in a research note on Wednesday, October 16th. They set an “outperform” rating for the company. Finally, Morgan Stanley started coverage on Apellis Pharmaceuticals in a report on Thursday, November 21st. They issued an “equal weight” rating and a $31.00 target price on the stock. Eight equities research analysts have rated the stock with a hold rating, ten have issued a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $46.71.

Institutional Investors Weigh In On Apellis Pharmaceuticals

Hedge funds have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its position in Apellis Pharmaceuticals by 23.3% in the third quarter. JPMorgan Chase & Co. now owns 3,884,730 shares of the company’s stock worth $112,036,000 after purchasing an additional 735,160 shares during the period. Braidwell LP grew its position in Apellis Pharmaceuticals by 410.8% during the 3rd quarter. Braidwell LP now owns 3,125,183 shares of the company’s stock worth $90,130,000 after acquiring an additional 2,513,383 shares during the last quarter. Jennison Associates LLC grew its holdings in shares of Apellis Pharmaceuticals by 51.6% during the fourth quarter. Jennison Associates LLC now owns 2,760,404 shares of the company’s stock worth $88,084,000 after purchasing an additional 939,289 shares during the last quarter. Assenagon Asset Management S.A. increased its position in Apellis Pharmaceuticals by 191.9% in the 3rd quarter. Assenagon Asset Management S.A. now owns 2,144,415 shares of the company’s stock valued at $61,845,000 after acquiring an additional 1,409,707 shares in the last quarter. Finally, Geode Capital Management LLC lifted its holdings in Apellis Pharmaceuticals by 1.3% during the 3rd quarter. Geode Capital Management LLC now owns 1,810,526 shares of the company’s stock worth $52,229,000 after buying an additional 22,609 shares in the last quarter. Institutional investors own 96.29% of the company’s stock.

Apellis Pharmaceuticals Company Profile

Apellis Pharmaceuticals, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, and hematopoietic stem cell transplantation-associated thrombotic microangiopathy; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA).